Terence Flynn: AI Opportunities in Healt...

It appears that credit investors have gotten most of what they’ve wished for over the last decade. Our Global Head of Fixed Income Research Andrew Sheets considers whether there could be unintended consequences.Read more insights from Morgan Stanley.----- Transcript ----- Andrew ... Show More

Our Head of Digital Asset Strategy Amy Oldenburg joins Global Digital Asset Strategist Felix Stratmann discuss how tokenization, regulation, and the convergence of traditional and digital finance could reshape global markets.Read more insights from Morgan Stanley.----- Transcript ... Show More

With Election Day a week away, our Head of U.S. Public Policy Research Ariana Salvatore and Wealth Management's Monica Guerra explain why the aftermath of the midterms may matter more to markets than who wins.Read more insights from Morgan Stanley.----- Transcript ----- Ariana Sa ... Show More

<p>Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI i ... Show More

Vaccine-maker Moderna is also a data company, and that’s enabling it to use AI to drastically reduce drug-development times, Chief Information Officer Brad Miller tells Bloomberg Intelligence’s Sam Fazeli and Mandeep Singh. This episode of the Tech Disruptors podcast looks at a w ... Show More

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ... Show More

Learn how agentic AI is transforming pharma. IQVIA’s Raja Shankar and Avinob Roy share how intelligent automation accelerates clinical trials, improves commercial strategy, and powers better patient care — turning healthcare data into outcomes at scale. Listen to the full archive ... Show More

<p><span data-preserver-spaces="true">Today's guest is Liran Belenzon, Co-founder and CEO of BenchSci. BenchSci is a global leader in AI solutions for preclinical R&D that helps decipher complex biomedical research using proprietary technology. Liran joins us to discuss how AI is ... Show More

The pharmaceutical industry has yet to develop highly effective treatments for common chronic and neurological issues, like Alzheimer’s and cardiovascular disease. But GenAI promises to accelerate the discovery and development of breakthrough treatments. BCG’s Priya Chandran expl ... Show More

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ... Show More

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ... Show More

Today's show: It's another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $1 ... Show More